Skip to main content

Baxter International Value Stock - Dividend - Research Selection

Baxter international

ISIN: US0718131099 , WKN: 853815

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Baxter International Inc. provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. The company also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors\' offices, and by patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Does Surgeon-Led Hemopatch Launch Mark a New Innovation Edge for Baxter (BAX)?

2025-08-30
On August 18, 2025, Baxter International unveiled its new Hemopatch sealing hemostat, a room-temperature collagen pad tailored for use in both open and minimally invasive surgeries, following a decade-long collaboration with medical experts. This product's development was driven by direct surgeon feedback, highlighting Baxter's approach of addressing specific, real-world clinical needs through practical innovation. We'll explore how delivering a new surgeon-informed hemostatic device could...

Is Baxter’s Sell-off an Opportunity for Long-Term Investors?

2025-08-29
Baxter International Inc. (NYSE:BAX) is one of the most undervalued and overlooked large-cap stocks. On August 4, a Barclays analyst lowered his price target on Baxter International Inc. (NYSE:BAX) to $36 from $41, while maintaining an Overweight rating. The cut followed a sharp 24% decline in the stock after Q2 results, driven by the pause of […]

The Bottom Fishing Club - Avanos Medical: Bargain Defensive Choice

2025-08-29
Discover why Avanos Medical, Inc. offers a compelling turnaround investment. Click for more on AVNS stock and why I think it is a bargain.

Medical Affairs Leader Dr. Kirk Shepard Joins BP Logix’s Life Sciences Strategic Advisory Board

2025-08-26
SAN DIEGO, August 26, 2025--As part of its mission to drive innovation in Medical Affairs automation, BP Logix is pleased to announce the appointment of Dr. Kirk Shepard to the company's Life Sciences Strategic Advisory Board.

Baxter, U.S. Physical Therapy, Cogent, HNI, and TD SYNNEX Stocks Trade Up, What You Need To Know

2025-08-22
A number of stocks jumped in the afternoon session after the major indices rebounded, as Fed Chair Jerome Powell delivered dovish remarks at the much-awaited Jackson Hole symposium. Powell suggested that with inflation risks moderating and unemployment remaining low, the Federal Reserve might consider a shift in its monetary policy stance, including potential interest rate cuts. This outlook eased market concerns about prolonged high interest rates and their impact on economic growth. The prospe

Medical Devices & Supplies - Diversified Stocks Q2 In Review: Baxter (NYSE:BAX) Vs Peers

2025-08-22
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Baxter (NYSE:BAX) and its peers.

Option Care Health taps new CFO

2025-08-21
Meenal Sethna will replace Michael Shapiro as the infusion therapy provider’s chief financial executive in October.

Macquarie Value Fund Q2 2025 Commentary

2025-08-17
For the second quarter, Macquarie Value Fund Institutional Class shares trailed its benchmark, the Russell 1000® Value Index. Read more here.

Is There An Opportunity With Baxter International Inc.'s (NYSE:BAX) 33% Undervaluation?

2025-08-15
NYSE:BAX 1 Year Share Price vs Fair Value Explore Baxter International's Fair Values from the Community and select...

Here’s Why You Should Consider Selling Your Baxter (BAX) Shares

2025-08-13
Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large-cap stocks, released its Parnassus Value Equity Fund second-quarter 2025 investor letter. The full letter is available for download here. For the second quarter of 2025, the fund reported a net return of 7.24%, outperforming its benchmark, the Russell 1000 […]